Literature DB >> 11016467

Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy.

T Irie1, J Kigawa, Y Minagawa, H Itamochi, S Sato, R Akeshima, N Terakawa.   

Abstract

AIMS: The aim of the present study was to evaluate the outcome of patients with stage lb-IIb cervical adenocarcinoma treated with radical hysterectomy, and to determine the clinicopathological characteristics of those patients.
METHODS: A total of 255 patients with cervical carcinoma stage Ib-IIb (57 adenocarcinoma and 198 squamous cell carcinoma) who had undergone radical hysterectomy were included in this study. Patient survival distribution was calculated using the Kaplan-Meier method.
RESULTS: The estimated 5-year survival rate for patients with adenocarcinoma was significantly poorer than that for patients with squamous cell carcinoma (77.9% vs 91.7%). The survival rate in stage Ib patients did not differ between two groups (95.8% vs 94.4% respectively). The incidence of lymph node involvement was significantly higher in patients with adenocarcinoma than in those with squamous cell carcinoma (31.6% vs 14.8%). Among patients receiving post-operative radiotherapy, the survival rate for adenocarcinoma (71.1%) was significantly poorer than that for squamous cell carcinoma (90.0%). When patients underwent radical hysterectomy, the survival rate for stage II patients with adenocarcinoma was significantly poorer than that for patients with squamous cell carcinoma.
CONCLUSIONS: The higher incidence of lymph node involvement and lower response to post-operative radiotherapy are considered to be factors of poorer prognosis in cervical adenocarcinoma.

Entities:  

Mesh:

Year:  2000        PMID: 11016467     DOI: 10.1053/ejso.1999.0923

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  25 in total

1.  Survival and prognosticators of node-positive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.

Authors:  Masayoshi Hosaka; Hidemichi Watari; Takashi Mitamura; Yousuke Konno; Tetsuji Odagiri; Tatsuya Kato; Mahito Takeda; Noriaki Sakuragi
Journal:  Int J Clin Oncol       Date:  2010-09-15       Impact factor: 3.402

2.  Increased expression of iASPP correlates with poor prognosis in FIGO IA2-IIA cervical adenocarcinoma following a curative resection.

Authors:  Fanming Kong; Xiaofeng Shi; Huzi Li; Pu Li; Jianchun Yu; XiaoJiang Li; Jun Chen; Yiyu Sun; Yingjie Jia
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

3.  Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.

Authors:  Muneaki Shimada; Shoji Nagao; Keiichi Fujiwara; Nobuhiro Takeshima; Ken Takizawa; Tadahiro Shoji; Toru Sugiyama; Satoshi Yamaguchi; Ryuichiro Nishimura; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2016-07-05       Impact factor: 3.402

4.  A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer.

Authors:  Xiuzhen Xie; Kun Song; Baoxia Cui; Jie Jiang; Xingsheng Yang; Beihua Kong
Journal:  Int J Clin Oncol       Date:  2018-01-03       Impact factor: 3.402

Review 5.  Adenocarcinoma of the cervix: should we treat it differently?

Authors:  Ned L Williams; Theresa L Werner; Elke A Jarboe; David K Gaffney
Journal:  Curr Oncol Rep       Date:  2015-04       Impact factor: 5.075

Review 6.  Adenocarcinoma of the uterine cervix: why is it different?

Authors:  Keiichi Fujiwara; Bradley Monk; Mojgan Devouassoux-Shisheboran
Journal:  Curr Oncol Rep       Date:  2014-12       Impact factor: 5.075

7.  Cytoplasmic Maspin Expression Correlates with Poor Prognosis of Patients with Adenocarcinoma of the Uterine Cervix.

Authors:  Kanae Nosaka; Yasushi Horie; Tatsushi Shiomi; Hiroaki Itamochi; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Tomohiko Sakabe; Tasuku Harada; Yoshihisa Umekita
Journal:  Yonago Acta Med       Date:  2015-12-18       Impact factor: 1.641

8.  (18)F-FDG PET in stage IB/IIB cervical adenocarcinoma/adenosquamous carcinoma.

Authors:  Hung-Hsueh Chou; Hsiu-Ping Chang; Chyong-Huey Lai; Koon-Kwan Ng; Swei Hsueh; Tzu-I Wu; Ming-Yu Chen; Tzu-Chen Yen; Ji-Hong Hong; Ting-Chang Chang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

9.  Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix.

Authors:  T Kasamatsu; T Onda; M Sawada; T Kato; S Ikeda; Y Sasajima; H Tsuda
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640

10.  Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.

Authors:  Kimberly Levinson; Anna L Beavis; Christopher Purdy; Anne F Rositch; Akila Viswanathan; Aaron H Wolfson; Michael G Kelly; Krishnansu S Tewari; Leah McNally; Saketh R Guntupalli; Omar Ragab; Yi-Chun Lee; David S Miller; Warner K Huh; Kelly J Wilkinson; Nicola M Spirtos; Linda Van Le; Yovanni Casablanca; Laura L Holman; Steven E Waggoner; Amanda N Fader
Journal:  Gynecol Oncol       Date:  2021-07-01       Impact factor: 5.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.